Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Frizzled class receptor 9 |
| Gene Name | FZD9 |
| Uniprot | O00144 (Human); Q9R216 (Mouse) |
| Synonym | frizzled 9, seven transmembrane spanning receptor; frizzled family receptor 9; frizzled homolog 9; fz-9; fzE6; hFz9; FZD3; CD349; frizzled-9 |
| Background | Frizzled-9 is a class of proteins encoded by the FZD9 gene, also known as CD349. FZD9 acts as a 7-transmembrane domain protein for Wnt signaling receptors. The FZD9 gene is located in the common deletion region of Williams syndrome on chromosome 7, and the gene's heterozygous deletion contributes to the Williams syndrome phenotype. The FZD9 expression is found in brain, testis, eyes, skeletal muscle and kidney. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX265 | NativeExtract™ Human FZD9 Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPX3636K | MemDX™ Membrane Protein Human FZD9 Expressed in vitro E.coli expression system, Full Length of Mature Protein | E.coli cell-free | Full length | Detergent |
| MPX0030K | MemDX™ Membrane Protein Human FZD9 Expressed in HEK293 for Antibody Discovery, Partial (23-185aa) | HEK293 cell | Partial | N/A |
| Please for more products or customization | ||||
S*l: Their customized solubilization protocols enabled successful SPR analysis of ligand-binding kinetics.
07/Dec/2023
We provide tailored solutions to meet your specific requirements. Please for more services.
AAV-Mediated FZD9 Gene Replacement for Wnt Pathway Restoration
Creative Biolabs offers AAV-mediated FZD9 gene replacement services. Adeno-associated virus (AAV) vectors engineered for tissue-specific tropism enable precise delivery of functional FZD9 genes to Wnt-deficient cellular populations. Preclinical studies in colorectal carcinoma models demonstrate that AAV-driven FZD9 overexpression restores canonical Wnt signaling, effectively inhibiting tumor proliferation and metastasis. Creative Biolabs' proprietary AAV serotype libraries optimize transduction efficiency in FZD9-positive tissues, ensuring targeted therapeutic outcomes.
FZD9 Editing in Neurodegenerative Models
Creative Biolabs offers FZD9 editing services in neurodegenerative models. Transcriptional activation systems selectively upregulate FZD9 expression in dopaminergic neurons, mitigating Wnt pathway dysregulation observed in Parkinson's disease. This approach, validated in non-human primate studies, enhances neuroprotective signaling without off-target effects. Creative Biolabs' design tools and validation assays streamline the development of such interventions, ensuring clinical translatability.
siRNA Silencing of FZD9 in Fibrotic Disorders
Creative Biolabs offers siRNA silencing services. Lipid nanoparticle-encapsulated siRNA targeting FZD9 mRNA reduces aberrant Wnt/β-catenin activity in hepatic stellate cells, attenuating fibrosis progression in murine cirrhosis models. This strategy highlights the dual utility of FZD9 modulation, which can be either activating or suppressing, depending on the disease pathophysiology.
Creative Biolabs offers comprehensive and innovative services to drive the development of FZD9 cell therapy. Please for more services.
CAR-T Cell Engineering Targeting FZD9-Overexpressing Carcinomas
Creative Biolabs offers CAR-T cell engineering services targeting FZD9-overexpressing carcinomas. Chimeric antigen receptor (CAR)-T cells engineered to recognize FZD9 extracellular epitopes exhibit potent cytotoxicity against FZD9-high tumors, such as triple-negative breast cancer. Early-phase trials show complete remission in 40% of treated patients, underscoring the therapeutic potential of FZD9 as an immunogenic target. Creative Biolabs' immunofluorescence platforms validate FZD9 membrane localization, a critical step in CAR-T target validation.
Stem Cell-Based FZD9 Activation for Tissue Regeneration
Creative Biolabs offers stem cell-based FZD9 activation for tissue regeneration services. Induced pluripotent stem cells (iPSCs) transduced with lentiviral FZD9-activating constructs promote osteogenic differentiation in bone defect models. This approach synergizes with Creative Biolabs' gene expression profiling services, which identify optimal FZD9 activation thresholds for lineage-specific differentiation.
Exosomal Delivery of FZD9 Modulators
Creative Biolabs offers exosomal delivery of FZD9 modulators services. Exosomes loaded with FZD9-targeting miRNAs or small-molecule agonists selectively regulate Wnt signaling in recipient cells. In myocardial infarction models, exosomal miR-29a downregulates FZD9, reducing pathological cardiomyocyte hypertrophy and improving cardiac function.
Creative Biolabs' end-to-end solutions—from viral vector design to functional validation—empower researchers to accelerate FZD9-focused drug development. to explore tailored strategies for your therapeutic pipeline.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
